01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
00:02 , Jun 26, 2019 |  BC Extra  |  Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
22:18 , Dec 26, 2018 |  BC Extra  |  Company News

FDA accepts Acer, Kala NDAs before funding lapse

FDA accepted for review NDAs from Acer Therapeutics Inc. (NASDAQ:ACER) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) before the partial government shutdown blocked the agency from taking on new user fee-based applications. The agency granted Priority Review...
23:20 , Dec 18, 2018 |  BC Extra  |  Company News

Management tracks: AbbVie, Semma, Ziopharm

AbbVie Inc. (NYSE:ABBV) unveiled a new executive leadership team. It includes EVP of R&D and CSO Michael Severino, who will become vice chairman and president and be responsible for R&D, HR, operations and the corporate...
20:12 , Jul 7, 2017 |  BC Week In Review  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
22:11 , Jul 3, 2017 |  BC Extra  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Clinical News

Celiprolol: Phase III data

Researchers at the hospital system and colleagues reported data from the open-label French and Belgian Phase III BBEST trial in 53 patients with vascular Ehlers-Danlos syndrome showing that celiprolol met the primary endpoint of significantly...